113 related articles for article (PubMed ID: 705679)
1. [Cardiovascular complications of oestrogen treatment in prostatic carcinoma (author's transl)].
Héritier P; Hessler D
Ther Umsch; 1978 Oct; 35(10):841-4. PubMed ID: 705679
[No Abstract] [Full Text] [Related]
2. [Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
Varenhorst E; Carlström K; Karlberg BE; Risberg B; Wallentin L; Wranne B
Urologe A; 1982 Jan; 21(1):34-8. PubMed ID: 6805122
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
Hedlund PO; Gustafson H; Sjögren S
Scand J Urol Nephrol Suppl; 1980; 55():103-5. PubMed ID: 6938012
[TBL] [Abstract][Full Text] [Related]
4. [Orchidectomy and oestrogen therapy of carcinoma of the prostate (author's transl)].
Straube W; Braun JS
Urologe A; 1974 Jul; 13(4 Pt A):198-201. PubMed ID: 4137442
[No Abstract] [Full Text] [Related]
5. [Carcinoma of the breast under estrogen-treatment for prostatic carcinoma (author's transl)].
Bülow H; Wullstein HK; Böttger G; Schröder FH
Urologe A; 1973 Sep; 12(5):249-53. PubMed ID: 4357698
[No Abstract] [Full Text] [Related]
6. Oestrogens: are they really dangerous? Groupe Coopératif d'étude sur le Cancer de la Prostate.
Prog Clin Biol Res; 1987; 243B():437-8. PubMed ID: 3659036
[No Abstract] [Full Text] [Related]
7. [Vascular accidents of estrogen therapy for prostatic cancer metastases].
Jurascheck F
J Urol Nephrol (Paris); 1973 Dec; 79(12 Pt 2):400-2. PubMed ID: 4804405
[No Abstract] [Full Text] [Related]
8. [Cardiovascular effects of estrogen in prostatic cancer].
Hedlund PO
Lakartidningen; 1981 May; 78(22):2215-7. PubMed ID: 7196479
[No Abstract] [Full Text] [Related]
9. [Cardiovascular risks induced by estrogens prescribed at low doses. 208 years of observation--137 patients].
Chevret S; Chastang C
Prog Urol; 1991 Apr; 1(2):281-5. PubMed ID: 1844829
[TBL] [Abstract][Full Text] [Related]
10. [Estrogens and postmenopause (author's transl)].
Rezaković-Musić D
Lijec Vjesn; 1981; 103(2-3):97-104. PubMed ID: 7031394
[No Abstract] [Full Text] [Related]
11. [Inhibition of platelet aggregation under estrogen-treatment in patients with carcinoma of the prostate (author's transl)].
Eisen M; Napp HE; Vock R
Urologe A; 1975 May; 14(3):132-6. PubMed ID: 1154559
[TBL] [Abstract][Full Text] [Related]
12. [Changes in hormonal homeostasis and development of disorders of the cardiovascular system in patients with prostatic cancer on estrogen therapy].
Gembitskiĭ EV; Begunov AV
Klin Med (Mosk); 1991 Dec; 69(12):59-63. PubMed ID: 1724022
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and survival data in carcinoma of the prostate.
Bennett AH; Dowd JB; Harrison JH
Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
[No Abstract] [Full Text] [Related]
14. [Hyperplasia of prolactin cells after estrogen therapy in carcinoma of the prostate (author's transl)].
Hachmeister U
Verh Dtsch Ges Pathol; 1972; 56():535-9. PubMed ID: 4130889
[No Abstract] [Full Text] [Related]
15. [The curative treatment of prostatic carcinoma (author's transl)].
Graber P
Ther Umsch; 1978 Oct; 35(10):845-8. PubMed ID: 705680
[No Abstract] [Full Text] [Related]
16. [Parenteral estrogen--a safe therapeutic alternative in prostatic cancer seen from the cardiovascular point of view?].
Henriksson P; Stege R; Collste L; Pousette A; Von Schoultz B; Carlström K
Lakartidningen; 1992 Oct; 89(42):3493-4, 3497. PubMed ID: 1435052
[No Abstract] [Full Text] [Related]
17. [Intra- and extracellular electrolyte concentration of estrogen therapy on patients with carcinoma of the prostate (author's transl)].
Kunze U; Orestano F
Urologe A; 1973 Sep; 12(5):274-7. PubMed ID: 4762689
[No Abstract] [Full Text] [Related]
18. [Prostatic carcinoma: metabolic effect of percutaneous beta-estradiol (author's transl)].
Steg A; Benoit G; Limouzin-Lamotte A; Mahoudeau J; Caillens M; Raichvarg D
Nouv Presse Med; 1979 Nov; 8(46):3801-2. PubMed ID: 534245
[TBL] [Abstract][Full Text] [Related]
19. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
Aro J; Ruutu M; Juusela H; Hansson E; Permi J
Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
[TBL] [Abstract][Full Text] [Related]
20. [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
Drawz B; Hoffmann L; Drawz G; Russbüldt R
Z Urol Nephrol; 1987 Mar; 80(3):171-5. PubMed ID: 3604473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
